Mitomycin Medac (Mitomycin)

Mitomycin is a bioreductive alkylating agent. Inside cancer cells it is reduced to a highly reactive intermediate that forms covalent bonds between DNA strands. These cross‑links block DNA replication and transcription, leading to cell cycle arrest and programmed cell death of rapidly dividing tumour cells.

The dosage of Mitomycin Medac is individualized by the treating oncologist based on the specific cancer type, treatment setting (intravenous or intravesical), patient weight, renal function and prior therapy. Only a qualified prescriber can determine the appropriate regimen.

Mitomycin is classified as contraindicated in pregnancy because it can cause fetal harm. It is also not recommended during breastfeeding, as it may be excreted in milk and affect the infant. Women of child‑bearing potential should use effective contraception and discuss risks with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Mitomycin differs from many alkylating agents because it requires enzymatic reduction to become active, giving it a unique mechanism of DNA cross‑linking. Compared with agents like cyclophosphamide, Mitomycin often shows activity in tumours resistant to other alkylators, but it also carries a distinct toxicity profile, especially pulmonary and renal risks.

Mitomycin Medac should be stored refrigerated between 2 °C and 8 °C. The vials must be kept in their original packaging, protected from light, and should never be frozen or shaken. Maintaining the cold chain preserves drug stability and potency.

The drug is supplied as a sterile injectable solution. For systemic therapy it is given intravenously, usually as an infusion over a defined period. For bladder cancer, a diluted solution is instilled directly into the bladder (intravesical) and retained for a prescribed dwell time under clinical supervision.

The most critical adverse events include severe bone‑marrow suppression leading to infection or bleeding, pulmonary fibrosis that can be irreversible, and renal toxicity that may progress to renal failure. Early recognition of symptoms and regular monitoring of blood counts, lung function and kidney parameters are essential.

Patients with known hypersensitivity to Mitomycin or any component of the formulation should avoid it. Those with severe renal impairment, uncontrolled infections, active pulmonary disease, or pregnant and lactating women are also contraindicated. The prescribing physician must evaluate each individual’s medical history before initiating therapy.